Internet Explorer 8 Warnung Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.

Portfolio Finder

Current Startups


Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.

Added to portfolio 13. Jan 2012
Max-Planck-Straße 15a
40699 Erkrath


Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

Added to portfolio 27. Dec 2016
Atriva Therapeutics GmbH
Christophstr. 32
D-72072 Tübingen


AudioCure Pharma specializes in the preclinical and clinical development of small molecules for the treatment of audiological and neurodegenerative diseases like sudden hearing loss, tinnitus, Parkinson’s and Alzheimer’s disease. In a first step the company focuses on sudden hearing loss.

Our compounds AC102 and AC002 have shown excellent efficacy in different animal models for the above-mentioned indications. Consequently, AudioCure is on its way to perform formal preclinical tests and to move AC102 into first-in-man testing.

Added to portfolio 20. Apr 2012
Schlegelstr. 9
10115 Berlin


Biametrics GmbH is a spin-off from the University of Tübingen. This innovative business produces label-free analysis devices for use in clinical diagnostics. Based on the patented technology of reflectometric interference spectroscopy (RIfS), these devices detect interaction between bio-molecules. These small, handy analysis devices are fast, robust and economical, and they are also suitable for mobile use – all the while involving very low detection limits.

Added to portfolio 13. Aug 2010
Auf der Morgenstelle 18
72076 Tübingen


Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.

Added to portfolio 03. May 2017
Cardior Pharmaceuticals GmbH
Carl-Neuberg-Str. 1
30625 Hannover

Corimmun (Exit)

Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.

Exit since June 2012.

In portfolio 29. Dec 2006 – 22. Jun 2012
Fraunhoferstr. 17
82152 Martinsried


Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill FDA, EU, ICH and GxP compliance regulations.

Added to portfolio 16. Oct 2014
Cunesoft GmbH
Luise-Ullrich-Strasse 20
80636 München


This innovative biotechnology company was founded in 2012 as a spin-out of the Institute for Molecular Microbiology and Biotechnology of the Westfälische Wilhelms-Universität in Münster. Cysal is active in the production of biopolymers, peptides, and especially dipeptides. Furthermore, Cysal specializes in developing biotechnology solutions in General.

Added to portfolio 27. Jun 2012
Technologiehof Münster
Mendelstraße 11
48149 Münster


Hapila's counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.

Added to portfolio 28. Aug 2008
Otto Schott Straße 9
7552 Gera


HepaRegeniX, founded in 2015, specializes in the discovery and development of small molecule kinase inhibitors. The management team, led by Dr. Wolfgang Albrecht, and scientific advisors have over 20 years of experience in the pharmaceutical industry with a proven track record in drug development and cover all disciplines along the value creation chain from early stage discovery through clinical proof-of-concept studies. The unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo A/S, coparion, High-Tech Gruenderfonds and Ascenion GmbH. Ascenion supported the acquisition of the exclusive IP rights.

Added to portfolio 14. Nov 2016
Otto Schott Straße 9
7552 Gera


HiperScan revolutionizes the spectrometry: With a microchip and a cheap single detector HiperScan creates new applications like handheld analyzing tools for the mass market.

Added to portfolio 23. Oct 2008
Weißeritzstraße 3
01067 Dresden


Production of chitin and chitosan-based high purity biopolymers. HMC develops new chitosan applications for the pharmaceutical industry, nanoparticles for drug delivery systems, and is a custom manufacturer of chitosan derivatives.

Added to portfolio 03. Jun 2008
Heinrich-Damerow-Straße 1
06120 Halle (Saale)


Immunservice GmbH develops biomimetic immune hormones, in particular interleukin-2, for safer, more effective and potentially curative therapies, especially in cancer.

Added to portfolio 20. Jul 2007
Christoph-Probst-Weg 4
20251 Hamburg

KSK Diagnostics

KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the time before therapy is started. In addition to the diagnosis of pathogens, KSK Diagnostics’ point-of-care tests are ideally suited to quickly and reliably clarifying issues related to tumour diagnostics.

Added to portfolio 03. Apr 2017
KSK Diagnostics GmbH
Königstraße 4a
22767 Hamburg


microDimensions develops and distributes software solutions and services for microscopic image alignment, processing and visualization.

Added to portfolio 11. Dec 2013
Rupert-Mayer-Str. 44 // 64.07
81379 München


MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.

Added to portfolio 21. Jan 2011
Eiermarkt 3c
30938 Burgwedel


OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.

Added to portfolio 17. Sep 2013
Robert-Rössle-Straße 10
13125 Berlin


Perora develops a polymer-based fat-binding medical device as a novel platform for weight management and the treatment of obesity.

Added to portfolio 03. Jun 2013
Im Neuenheimer Feld 518
69120 Heidelberg

Provecs Medical (Exit)

Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system.

Exit since July 2015.

In portfolio 25. Apr 2007 – 28. Jul 2015
Martinistraße 52
20246 Hamburg

Rigontec (Exit)

Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I).

In portfolio 13. Jun 2014 – 06. Sep 2017
Biomedizinisches Zentrum, Gebäude 344
Sigmund-Freud-Str. 25
53127 Bonn

Rodos BioTarget

Development of novel therapeutic approaches addressing infectious and autoimmune diseases as well as cancers via immune cell-specific targeting.

Added to portfolio 29. Dec 2008
Feodor-Lynen-Straße 23
30625 Hannover


Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.

Added to portfolio 14. Nov 2016
Signatope GmbH
Markwiesenstr. 55
72770 Reutlingen


SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A goal is to develop optimized cell systems for the optimized vaccine, antibody or protein production

Added to portfolio 04. Sep 2007
Am Klopferspitz 19
82152 Planegg Martinsried


Thermosome develops novel drugs for locally-advanced solid tumors by using nanocarriers for heat-induced local drug delivery and thereby reaches up to 15 fold higher local drug concentrations.

Added to portfolio 15. Oct 2015
Am Klopferspitz 19 (IZB)
82152 Planegg/Martinsried


TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Added to portfolio 21. Dec 2016
TolerogenixX GmbH
Im Neuenheimer Feld 162
69120 Heidelberg


Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.

Added to portfolio 03. Sep 2007
Roesslerstraße 83
64293 Darmstadt